Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways

Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways

Abstract Background We investigated antitumor activity and underlying mechanisms of DNA topoisomerase I (TopI) inhibitor gimatecan and irinotecan in gastric cancer (GC) in vitro cell lines and in vivo patient-derived xenograft (PDX) models. Methods GC cell lines SNU-1, HGC27, MGC803 and NCI-N87 were...

Full description

Bibliographic Details
Main Authors: Zuhua Chen, Zhentao Liu, Wenwen Huang, Zhongwu Li, Jianling Zou, Jingyuan Wang, Xiaoting Lin, Beifang Li, Dongshao Chen, Yanting Hu, Jiafu Ji, Jing Gao, Lin Shen
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Journal of Translational Medicine
Subjects:
Gimatecan
Patient-derived xenografts
Gastric cancer
MAPK pathway
Online Access:http://link.springer.com/article/10.1186/s12967-017-1360-z

Internet

http://link.springer.com/article/10.1186/s12967-017-1360-z

Similar Items